Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 13/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2992957 | 0.85 | ERN1 (0.44) | ERN1TRIM24TRIM33KDM4EMEN1 | |
| SCHEMBL24947173 | 0.78 | CYP19A1 (0.32) | — | |
| SCHEMBL2263495 | 0.77 | ERN1 (0.37) | ERN1KDM4EMEN1KMT2A | |
| SCHEMBL24339440 | 0.77 | ALDH1A1 (0.38) | ERN1TRIM24TRIM33KDM4EMEN1 | |
| SCHEMBL21625594 | 0.77 | PTPN1 (0.37) | ERN1MEN1KMT2A | |
| SCHEMBL9483980 | 0.77 | IDO1 (0.39) | KDM4EIDO1L3MBTL1 | |
| SCHEMBL5153707 | 0.76 | ESR1 (0.40) | ERN1TRIM24TRIM33KDM4ENPC1 | |
| SCHEMBL28878024 | 0.73 | HTR2C (0.40) | ERN1 | |
| SCHEMBL2264012 | 0.73 | ALDH1A1 (0.43) | ERN1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL27296690 | 0.70 | ERN1 (0.43) | ERN1TRIM24TRIM33KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4464696-A1 | CHEMICALLY DEGRADABLE EPOXY COMPOUND, METHOD FOR PREPARING SAME, EPOXY COMPOSITE MATERIAL COMPRISING SAME, AND DECOMPOSITION METHOD THEREOF | Konkuk University Industrial Cooperation Corp. (KR) | 2024-11-20 | — | — | EP | claimed |
| US-20230365742-A1 | CHEMICALLY DEGRADABLE EPOXY COMPOUND, METHOD OF PREPARING SAME COMPOUND, EPOXY COMPOSITE MATERIAL CONTAINING SAME COMPOUND, AND METHOD OF DEGRADING SAME COMPOSITE MATERIAL | KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP (KR) | 2023-11-16 | — | — | US | claimed |
| WO-2023136620-A1 | CHEMICALLY DEGRADABLE EPOXY COMPOUND, METHOD FOR PREPARING SAME, EPOXY COMPOSITE MATERIAL COMPRISING SAME, AND DECOMPOSITION METHOD THEREOF | 건국대학교 산학협력단 | 2023-07-20 | — | — | WO | claimed |
| EP-4464696-A1 | CHEMICALLY DEGRADABLE EPOXY COMPOUND, METHOD FOR PREPARING SAME, EPOXY COMPOSITE MATERIAL COMPRISING SAME, AND DECOMPOSITION METHOD THEREOF | Konkuk University Industrial Cooperation Corp. (KR) | 2024-11-20 | — | — | EP | disclosed |
| US-20230365742-A1 | CHEMICALLY DEGRADABLE EPOXY COMPOUND, METHOD OF PREPARING SAME COMPOUND, EPOXY COMPOSITE MATERIAL CONTAINING SAME COMPOUND, AND METHOD OF DEGRADING SAME COMPOSITE MATERIAL | KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP (KR) | 2023-11-16 | — | — | US | disclosed |
| EP-1381366-B9 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2009-10-21 | — | — | EP | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1381366-B1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| EP-1768694-A1 | PHAMACEUTICAL PREPARATIONS COMPRISING INSULIN | NOVO NORDISK A/S (DK) | 2007-04-04 | — | — | EP | disclosed |
| US-20060258561-A1 | Novel NPH insulin preparations | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | US | disclosed |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | NOVO NORDISK A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| WO-2006005683-A1 | PHAMACEUTICAL PREPARATIONS COMPRISING INSULIN | NOVO NORDISK A/S (DK) | 2006-01-19 | — | — | WO | disclosed |
| EP-1610812-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2006-01-04 | — | — | EP | disclosed |
| EP-1605967-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2005-12-21 | — | — | EP | disclosed |
| EP-1585541-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2005-10-19 | — | — | EP | disclosed |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | NOVO NORDISK A/S (DK) | 2005-03-24 | — | — | US | disclosed |
| WO-2004080481-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004080480-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004056347-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258561-A1 | Novel NPH insulin preparations | IAPP, HBB, INSR | ERN1 2020/4885TRIM24 1288/4885TRIM33 2962/4885 |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | IAPP, GPR119, INSR | ERN1 2642/4885TRIM24 355/4885TRIM33 1505/4885 |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | IAPP, IRS1, INSR | ERN1 1968/4885TRIM24 227/4885TRIM33 1101/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | ERN1 3255/4885TRIM24 318/4885TRIM33 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.